EE427 Annual Cost Savings From the Use of Empagliflozin Over DPP4I in Select Asia-Pacific Countries – Estimates Based on the Emprise East Asia Study
- Resource Type
- Abstract
- Source
- In
Value in Health December 2022 25(12) Supplement:S139-S139 - Subject
- Language
- ISSN
- 1098-3015